Skip to main content
SpringerLink
Log in

Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few reports to date have discussed optimal conditioning regimens. Herein, we report two cases of NL in patients with relapsed intravascular large B-cell lymphoma who received consolidative thiotepa-containing HDC-ASCT. Case 1: A 56-year-old woman who relapsed 2 months after the first complete remission (CR) and underwent ASCT. Case 2: A 65-year-old woman who relapsed 8 months after the first CR and underwent ASCT. Both patients engrafted. Time to neutrophil engraftment was 10 and 12 days after HDC-ASCT, and CR was sustained for 26 and 18 months, respectively, as of the last follow-up. Although there is little evidence supporting the utility of thiotepa-based HDC-ASCT in patients with NL, the results of this case report suggest that further studies are warranted to determine its efficacy in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Davidson T, Kedmi M, Avigdor A, Komisar O, Chikman B, Lidar M, et al. FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes. Leuk Lymphoma. 2018;59(2):348–56. https://doi.org/10.1080/10428194.2017.1352096.

    Article  PubMed  Google Scholar 

  2. DeVries AH, Howe BM, Spinner RJ, Broski SM. B-cell peripheral neurolymphomatosis: MRI and (18)F-FDG PET/CT imaging characteristics. Skeletal Radiol. 2019;48(7):1043–50. https://doi.org/10.1007/s00256-019-3145-3.

    Article  PubMed  Google Scholar 

  3. Kinoshita H, Yamakado H, Kitano T, Kitamura A, Yamashita H, Miyamoto M, et al. Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases. J Neurol. 2016;263(9):1719–26. https://doi.org/10.1007/s00415-016-8190-4.

    Article  PubMed  Google Scholar 

  4. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2010;115(24):5005–11. https://doi.org/10.1182/blood-2009-12-258210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Khurana A, Novo M, Nowakowski GS, Ristow KM, Spinner RJ, Hunt CH, et al. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021;5(5):1379–87. https://doi.org/10.1182/bloodadvances.2020003666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Byun JM, Kim KH, Kim M, Kim TM, Jeon YK, Park JH, et al. Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. Leuk Lymphoma. 2017;58(11):2624–32. https://doi.org/10.1080/10428194.2017.1312376.

    Article  PubMed  Google Scholar 

  7. Ubogu EE. Biology of the human blood-nerve barrier in health and disease. Exp Neurol. 2020;328:113272. https://doi.org/10.1016/j.expneurol.2020.113272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro Oncol. 2003;5(2):104–15. https://doi.org/10.1093/neuonc/nop021.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kamiya-Matsuoka C, Shroff S, Gildersleeve K, Hormozdi B, Manning JT, Woodman KH. Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes. J Neurol Sci. 2014;343(1–2):144–8. https://doi.org/10.1016/j.jns.2014.05.058.

    Article  PubMed  Google Scholar 

  10. Lagarde S, Tabouret E, Matta M, Franques J, Attarian S, Pouget J, et al. Primary neurolymphomatosis diagnosis and treatment: a retrospective study. J Neurol Sci. 2014;342(1–2):178–81. https://doi.org/10.1016/j.jns.2014.04.030.

    Article  CAS  PubMed  Google Scholar 

  11. Kobayashi H, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, et al. Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis. Int J Hematol. 2019;109(3):286–91. https://doi.org/10.1007/s12185-018-02586-7.

    Article  CAS  PubMed  Google Scholar 

  12. Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(4):593–602. https://doi.org/10.1016/s1470-2045(20)30059-0.

    Article  CAS  PubMed  Google Scholar 

  13. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, et al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101(6):1480–6. https://doi.org/10.1111/j.1349-7006.2010.01555.x.

    Article  CAS  PubMed  Google Scholar 

  14. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7(7):993–1003. https://doi.org/10.1001/jamaoncol.2021.1074.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N, N’, N" -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000;26(4):257–68. https://doi.org/10.1053/ctrv.2000.0170.

    Article  CAS  PubMed  Google Scholar 

  16. Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, et al. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the japan society for hematopoietic cell transplantation Registry. Biol Blood Marrow Transplant. 2019;25(5):899–905. https://doi.org/10.1016/j.bbmt.2019.01.020.

    Article  CAS  PubMed  Google Scholar 

  17. Kondo E, Ikeda T, Goto H, Nishikori M, Maeda N, Matsumoto K, et al. Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. Cancer Chemother Pharmacol. 2019;84(4):849–60. https://doi.org/10.1007/s00280-019-03914-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, et al. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022;115(3):391–8. https://doi.org/10.1007/s12185-021-03263-y.

    Article  CAS  PubMed  Google Scholar 

  19. Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol. 2010;12(2):212–5. https://doi.org/10.1093/neuonc/nop021.

    Article  PubMed  Google Scholar 

  20. Richner M, Ferreira N, Dudele A, Jensen TS, Vaegter CB, Gonçalves NP. Functional and structural changes of the blood-nerve-barrier in diabetic neuropathy. Front Neurosci. 2018;12:1038. https://doi.org/10.3389/fnins.2018.01038.

    Article  PubMed  Google Scholar 

  21. Matsue K, Hayama BY, Iwama K, Koyama T, Fujiwara H, Yamakura M, et al. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. Cancer. 2011;117(19):4512–21. https://doi.org/10.1002/cncr.26090.

    Article  PubMed  Google Scholar 

  22. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol. 2002;59(3):439–43. https://doi.org/10.1001/archneur.59.3.439.

    Article  PubMed  Google Scholar 

  23. Vandenheede M, Dioh A, de Noordhout AM, Deprez M, Schoenen J. Intravascular malignant lymphomatosis: report of 2 neurological cases. Acta Neurol Belg. 2002;102(2):76–81.

    PubMed  Google Scholar 

  24. Lynch KM, Katz JD, Weinberg DH, Lin DI, Folkerth RD. Isolated mononeuropathy multiplex–a rare manifestation of intravascular large B-cell lymphoma. J Clin Neuromuscul Dis. 2012;14(1):17–20. https://doi.org/10.1097/CND.0b013e318262ab5c.

    Article  PubMed  Google Scholar 

  25. Yamada S, Tanimoto A, Nabeshima A, Tasaki T, Wang KY, Kitada S, et al. Diffuse large B-cell lymphoma presenting with neurolymphomatosis and intravascular lymphoma: a unique autopsy case with diverse neurological symptoms. Diagn Pathol. 2012;7:94. https://doi.org/10.1186/1746-1596-7-94.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Porzionato A, Pelletti G, Barzon L, Contran M, Emmi A, Arminio A, et al. Intravascular large B-cell lymphoma affecting multiple cranial nerves: a histopathological study. Neuropathology. 2021;41(5):396–405. https://doi.org/10.1111/neup.12767.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Tanaka Y, Momose S, Takayanagi N, Tabayashi T, Tokuhira M, Tamaru JI, et al. Rapid deterioration of intravascular large B-cell lymphoma with mass formation in the trigeminal nerve and multiple organ infiltration: an autopsy case report. J Clin Exp Hematop. 2022;62(1):41–5. https://doi.org/10.3960/jslrt.21013.

    Article  PubMed  Google Scholar 

  28. Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood. 2021;137(11):1491–502. https://doi.org/10.1182/blood.2020007245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407. https://doi.org/10.1056/NEJMoa1801445.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90. https://doi.org/10.1038/s41591-018-0016-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ollila TA, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel NR, et al. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood. 2021;137(8):1120–4. https://doi.org/10.1182/blood.2020007236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood Disorders Center, Aiiku Hospital, Sapporo, Japan

    Toru Miyajima, Reiki Ogasawara, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Akio Mori, Makoto Saito, Masanobu Morioka & Takeshi Kondo

  2. Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, N15W7, Kita‑ku, Sapporo, 060‑8638, Japan

    Toru Miyajima

Authors
  1. Toru Miyajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reiki Ogasawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shihori Tsukamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Ishio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emi Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koh Izumiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akio Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Makoto Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masanobu Morioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toru Miyajima.

Ethics declarations

Conflict of interest

TK received honoraria from Bristol Meyers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Abbvie, Astellas and Nippon Shinyaku. The other authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyajima, T., Ogasawara, R., Tsukamoto, S. et al. Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis. Int J Hematol 118, 141–145 (2023). https://doi.org/10.1007/s12185-023-03544-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-023-03544-8

Keywords

Search

Navigation